Chinese Bio-pharmaceutical Company TOT Biopharm Raises $102M Series B Round


Suzhou-based bio-pharmaceutical company TOT Biopharm has raised US$102 million series B round led by Chinese local asset management 99Fund, according to the company’s announcement. Existing investors including Centerlab Group, Vivo Capital, Chengwei Capital, Yuanda Financial Holdings, and Gold Tech Venture Capital, as well as a number of well-known investment institutions in China and abroad also participated in this round. Founded in 2010, TOT Biopharm develops, manufactures, and markets anti-tumor drugs. It specializes in therapeutic biological products, anti-tumor drugs, and specialty …

Chinese Bio-pharmaceutical Company TOT Biopharm Raises $102M Series B Round appeared first on China Money Network.


Print Print | Email Email | Category: China News

Sorry, comments are closed at this time.